American Society of Clinical Oncology

SHERPA: White

People

  1. Hudis
    Hudis
  2. Scher
    Scher
  3. Motzer
    Motzer
  4. Saltz
    Saltz
  5. Kris
    Kris
  6. Bajorin
    Bajorin
  7. Norton
    Norton
  8. Patil
    Patil
  9. Wolchok
    Wolchok
  10. Morris
    Morris

Groups

  1. Solid Tumor Oncology Division (2144)
  2. Surgery (848)
  3. Genitourinary Disease Management Team (783)
  4. Survivorship Research (754)
  5. Genitourinary Oncology Service (700)
  6. Epidemiology and Biostatistics (624)
  7. Population Sciences Research Program (621)
  8. Breast Cancer Disease Management Team (618)
  9. Gastrointestinal Disease Management Team (601)
  10. Thoracic Malignancies Disease Management Team (572)
Search Within
Refine Results
Formats
  1. Meeting Abstract (2080)
  2. Journal Article (1844)
  3. Conference Paper (1)
Groups
  1. Solid Tumor Oncology Division (2144)
  2. Surgery (848)
  3. Genitourinary Disease Management Team (783)
  4. Survivorship Research (754)
  5. Genitourinary Oncology Service (700)
  6. Epidemiology and Biostatistics (624)

More Groups

People
  1. Robert Motzer (207)
  2. Howard Scher (204)
  3. Clifford Hudis (198)
  4. Leonard Saltz (174)
  5. Dean Bajorin (148)
  6. Mark Kris (143)

More People

Years
  1. 2019 (9)
  2. 2018 (231)
  3. 2017 (114)
  4. 2016 (216)
  5. 2015 (508)
  6. 2014 (446)

More Years

Publications
  1. Journal of Clinical Oncology (3732)
  2. Journal of Oncology Practice (103)
  3. American Society of Clinical Oncology Educational Book (88)
  4. ASCO Connection (1)
  5. ASCO News & Forum (1)

Results (3925)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Geriatric communication skills training: Shared decision making and care planning for the older cancer patient and the caregiver
    Meeting Abstract

    Manna, R.; Banerjee, S. C.; Shen, M. J.; Korc-Grodzicki, B.; Alici, Y.; Gangai, N.; Alexander, K.; Holland, J.; Parker, P. A.; Nelson, C. J.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A multicenter, randomized, controlled trial comparing the occurrence of major adverse cardiovascular events (MACEs) in patients (pts) with prostate cancer (pc) and cardiovascular disease (CVD) receiving degarelix (GnRH receptor antagonist) or leuprolide (GnRH receptor agonist)
    Meeting Abstract

    Slovin, S. F.; Melloni, C.; Mansor-Lefebvre, S.; Neijber, A.; Roe, M.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Transcriptomic heterogeneity of androgen receptor activity in primary prostate cancer: Identification and characterization of a low AR-active subclass
    Meeting Abstract

    Spratt, D. E.; Alshalalfa, M.; Weiner, A.; Fishbane, N.; Mehra, R.; Walter, R.; Erho, N.; Dicker, A.; Freedland, S. J.; Karnes, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC)
    Meeting Abstract

    Tannir, N. M.; Fan, A. C.; Lee, R. J.; Carthon, B. C.; Iliopoulos, O.; Mier, J. W.; Patel, M. R.; Meric-Bernstam, F.; DeMichele, A.; Voss, M. H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Pre-operative chemotherapy (ctx) in plasmacytoid urothelial carcinoma (PUC)
    Meeting Abstract

    Teo, M. Y.; Al-Ahmadie, H.; Seier, K.; Ostrovnaya, I.; Regazzi, A. M.; Dalbagni, G.; Bochner, B. H.; Funt, S.; Iyer, G.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Comparative effectiveness of bladder-preserving tri-modality therapy versus radical cystectomy for muscle-invasive bladder cancer
    Meeting Abstract

    Royce, T. J.; Feldman, A. S.; Mossanen, M.; Yang, J. C.; Shipley, W. U.; Pandharipande, P.; Efstathiou, J. A.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Validation of nuclear-localized AR-V7 on circulating tumor cells (CTC) as a treatment-selection biomarker for managing metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Scher, H. I.; Graf, R. P.; Schreiber, N. A.; Winquist, E.; McLaughlin, B.; Lu, D.; Orr, S.; Fleisher, M.; Lowes, L.; Anderson, A. K. L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician's choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
    Meeting Abstract

    Ryan, C. J.; Abida, W.; Bryce, A. H.; Balar, A. V.; Dumbadze, I.; Given, R. W.; Morris, D.; Petrylak, D. P.; Redfern, C. H.; Scher, H. I.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Clinical outcomes following biochemical recurrence among patients with Gleason score 9-10 prostate adenocarcinoma
    Meeting Abstract

    Sandler, K. A.; Chu, F. I.; Ciezki, J. P.; Stock, R.; Merrick, G. S.; Demanes, D. J.; Spratt, D. E.; Abu-Isa, E. I.; Pomerantz, M.; Ross, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study
    Meeting Abstract

    Sharma, P.; Callahan, M. K.; Bono, P.; Kim, J. W.; Spiliopoulou, P.; Calvo, E.; Pillai, R. N.; Ott, P. A.; De Braud, F. G.; Morse, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save